Second drug approved for DMD
نویسندگان
چکیده
منابع مشابه
Approved: Second certification option for nursing care centers.
Perspectives, pages 8–13), The Joint Commission will implement new memory care accreditation requirements for nursing care centers effective July 1, 2014. To build on these new requirements, which have been designed in response to the prevalence of dementia in nursing homes, The Joint Commission will also offer a new optional certification product for accredited nursing care centers. The option...
متن کاملBehaviour therapy for obesity treatment considering approved drug therapy
INTRODUCTION Obesity is a worldwide health problem whose prevalence is on the increase. Many obesity-associated diseases require intensive medical treatment and are the cause of a large proportion of health-related expenditures in Germany. Treatment of obesity includes nutritional, exercise and behaviour therapy, usually in combination. The goal of behaviour therapy for obesity is to bring abou...
متن کامل, Dmd
Prosthodontics, Scranton, Pennsylvania. ter of routine. However, in anterior implant -supported restorations, the successful achievement of the aesthetic goal can often be elusive. The task is made especially arduous when the potential implant recipient site lies within the lip perimeter and is compromised by significant hard and soft tissue defects and/or inharmonious occlusal combinations. Un...
متن کاملExon skipping for DMD
Duchenne muscular dystrophy (DMD) is a severe, progressive muscle-wasting disorder, while Becker muscular dystrophy (BMD) is milder muscle disease [1]. Both are caused by mutations in dystrophin, a protein, which stabilizes muscle fibers during contraction by linking muscle actin to the extracellular matrix. In DMD patients mutations disrupt the open reading frame, generating prematurely trunca...
متن کاملSecond-generation compound for the modulation of utrophin in the therapy of DMD
Duchenne muscular dystrophy (DMD) is a lethal, X-linked muscle-wasting disease caused by lack of the cytoskeletal protein dystrophin. There is currently no cure for DMD although various promising approaches are progressing through human clinical trials. By pharmacologically modulating the expression of the dystrophin-related protein utrophin, we have previously demonstrated in dystrophin-defici...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pharmacy Today
سال: 2017
ISSN: 1042-0991
DOI: 10.1016/j.ptdy.2017.03.014